Oxford-based Ultromics, which has developed the first FDA-cleared, Medicare-reimbursed AI tools for cardiology diagnostics, raised a $55M Series C — The funding will accelerate Ultromics' mission to advance heart disease detection and scale EchoGo®, its AI platform for earlier, more accurate diagnoses.
Posted from: this blog via Microsoft Power Automate.
